NEW YORK (GenomeWeb News) – Eurogentec said today that it has reached an agreement to acquire proteomics company AnaSpec for an undisclosed sum.

The agreement will give Eurogentec the potential to offer both genomics and proteomics tools for biotech, pharmaceutical, and diagnostics markets, the company said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.